Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Semaglutide30 residuesHEGTFTSDVSSYLEGQAAKEFIAWLVRGRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Ozempic, Wegovy, Wegovy HD
Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist with four FDA approvals and the largest cardiovascular outcomes trial ever run for a weight loss drug. The STEP 1 trial showed 14.9% mean weight loss at 68 weeks in 1,961 adults, and the newer 7.2 mg dose pushed that to 20.7% in STEP UP. The SELECT trial (17,604 participants) showed a 20% reduction in heart attacks, strokes, and cardiovascular death. Brand pricing runs $1,349 per month, though the oral tablet approved in December 2025 brought self-pay costs down to $149 per month. GI side effects are common during dose titration, and roughly two-thirds of the weight returns within a year of stopping.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (n=1,961)[1], turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT [2] confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (n=751), semaglutide 2.4 mg produced 13.7% weight loss versus 20.2% for tirzepatide 15 mg at 72 weeks. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (n=17,604)[2] confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
Semaglutide mimics the incretin hormone GLP-1, binding to GLP-1 receptors at three sites that each do something different. In the pancreas, receptor activation triggers glucose-dependent insulin secretion. Blood sugar drops, but only when it needs to. That glucose-dependent mechanism is why hypoglycemia is rare as monotherapy. In the gut, semaglutide slows gastric emptying. Food stays in the stomach longer; satiety lasts hours past a meal. This same mechanism causes the nausea during titration. The third site is the hypothalamus. GLP-1 receptor activation in the brain's satiety centers reduces appetite at a neurological level. Community members describe this as "food noise going silent." Obsessive food thoughts quiet within 2 to 4 weeks for most users. A fatty acid side chain (C18 diacid) lets semaglutide bind to serum albumin. That albumin binding slows clearance and extends the half-life to approximately 168 hours (7 days). Subcutaneous bioavailability sits at 89% (FDA prescribing information, Section 12.3). Peak plasma concentration arrives 1 to 3 days post-injection. SELECT [2] confirmed anti-atherosclerotic and anti-inflammatory effects beyond weight loss alone. The cardiovascular benefit held regardless of BMI or weight loss magnitude, pointing to direct vascular mechanisms still being characterized.
Unambiguous efficacy across three FDA indications (obesity, T2D, CV risk reduction). Most well-studied weight-loss drug in modern medicine with 15%+ mean weight loss in RCTs, 20% MACE reduction in SELECT (n=17,604), and a new 7.2 mg dose achieving 20.7% loss in STEP UP (FDA-approved March 2026). Evidence base is the strongest of any weight-loss intervention.
STEP 1 (NEJM 2021, PMID 33567185): n=1,961, 14.9% mean weight loss at 68 wk vs. 2.4% placebo. SELECT (NEJM 2023, PMID 37952131): n=17,604, HR 0.80 (95% CI 0.72–0.90) for MACE. STEP UP (2025): n=1,407, 20.7% loss with 7.2 mg at 72 wk; 33.2% of patients lost ≥25%. OASIS 4: oral 25 mg, 16.6% weight loss at 64 wk.
Two-thirds of weight regained within 1 year of stopping (STEP 1 extension). ~25–40% of weight lost is lean mass without active resistance training. Black box warning for thyroid C-cell tumors (rodent data; human risk unknown). Long-term data beyond 4 years limited. Dysesthesia 18.9% at 7.2 mg vs. 0% placebo (STEP UP): AE profile still being characterized.
Highest-discussed weight-loss intervention on Reddit by a wide margin (350k+ combined members across r/Ozempic and r/semaglutide). Broadly positive: appetite suppression ("food noise going silent") is the defining experience. Primary concerns: GI side effects during titration, cost, lean mass loss, and dread of weight regain after stopping.
Science and community strongly agree on efficacy magnitude, GI side effect profile, and weight regain kinetics after stopping. Primary divergence: the community endorses microdosing and dose-splitting with no clinical support. Community appetite-suppression reports sometimes exceed trial averages: consistent with satisfaction-bias in self-reporting. Community is ahead of clinical guidelines on lean mass loss awareness; the resistance training + protein co-intervention recommendation spread through Reddit before it entered mainstream prescribing guidance.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250mcg | Weekly |
| Moderate | 500mcg | Weekly |
| Aggressive | 1mg | Weekly |
Semaglutide ships in pre-filled brand pens (Wegovy, Ozempic, Wegovy HD) that require no reconstitution. For compounded vials, the math matters. 5 mg vial reconstituted with 2 mL bacteriostatic water = 2,500 mcg/mL. On a 100-unit insulin syringe, each unit equals 25 mcg. So your 250 mcg starting dose is 10 units; 500 mcg is 20 units; 1,000 mcg is 40 units; 2,400 mcg maintenance is 96 units. 10 mg vial in 2 mL = 5,000 mcg/mL. Each unit equals 50 mcg. Starting dose of 250 mcg is 5 units; 500 mcg is 10 units; 1,000 mcg is 20 units; 2,400 mcg is 48 units. Titrate slowly. Four weeks at each dose level is the FDA minimum, but experienced users commonly hold 6 to 8 weeks per step. Rushing the titration is the single most common beginner mistake; it makes nausea worse and does not speed up weight loss. You can always stay at a lower dose if appetite suppression is sufficient. Refrigerate compounded vials at 2 to 8 degrees Celsius and use within 6 weeks of reconstitution.
Semaglutide is typically used long-term. Weight regain commonly occurs after discontinuation. Discuss with your provider before stopping.
Semaglutide is designed for indefinite long-term use: there is no pharmacological rationale for cycling on/off (no receptor desensitization, hormonal axis suppression, or antibody formation that would improve with breaks). The cyclingProtocol in peptides.ts (onWeeks: 52, offWeeks: 0) correctly reflects a continuous-use medication. Cycling framing here applies only to scheduled safety monitoring intervals (labs every 3–6 months, body composition every 6 months) and formal dose re-evaluation periods. Weight regain is rapid on discontinuation: the concept of "cycling off" is medically counterproductive for most patients.
Or use the universal Peptide Calculator for any peptide.
Expected: 14.9% mean body weight loss at 68 weeks (STEP 1, n=1,961). One-third of patients achieve ≥20% loss. If inadequate response at 2.4 mg, Wegovy HD 7.2 mg is now FDA-approved.
Monitor: HbA1c, lipid panel, CMP (renal function) at baseline and every 3–6 months. Resting heart rate at every visit. DEXA body composition at baseline and every 6 months.
Physician & Longevity Specialist
39% of weight loss was lean mass — resistance training is essential alongside GLP-1 therapy.
Naturopathic Doctor & Conservative Dosing Advocate
Dose up to appetite control, not suppression. Interventions are scaffolding, not crutches.
Gather your vial (or pre-filled pen), alcohol swabs, and a 29 to 31 gauge insulin syringe (0.5 mL or 1 mL depending on your dose volume).
For a 5 mg/2 mL vial: 10 units = 250 mcg, 20 units = 500 mcg, 40 units = 1,000 mcg, 96 units = 2,400 mcg. For a 10 mg/2 mL vial: 5 units = 250 mcg, 10 units = 500 mcg, 20 units = 1,000 mcg, 48 units = 2,400 mcg.
Abdomen, thigh, or upper arm all work. Rotate sites each week.
Pinch the skin gently and insert the needle at a 90-degree angle. Inject slowly; hold for 5 to 10 seconds before removing.
Consistency matters more than time of day. Some users find that injecting in the evening reduces daytime nausea; others prefer morning.
In-use Ozempic pen is stable at room temperature up to 56 days. In-use Wegovy pen up to 28 days. Compounded vials: refrigerate and use within 28 to 42 days per pharmacy guidance.
Titration: 3 mg → 7 mg → 14 mg → 25 mg daily. Peak oral bioavailability is ~1% (SNAC-mediated) vs. ~89% for SC injection: the 25 mg oral dose is calibrated to match 2.4 mg SC pharmacokinetic exposure. Equivalent efficacy demonstrated in OASIS program.
Must be taken fasted with ≤4 oz plain water, ≥30 min before any food, other liquids, or oral medications. SNAC absorption enhancer is sensitive to food, coffee, juice, and other pills. Self-pay pricing via NovoCare: $149/month (starting doses), $349/month (higher doses). Eliminates injection anxiety and reconstitution risk: the most important option for needle-averse patients.
Lower doses (7–14 mg daily) than the obesity oral tablet (25 mg). Distinct indication and insurance coverage from Wegovy pill.
Same fasting administration requirements as Wegovy pill. A1c reduction of 1.0–1.4% at 14 mg (PIONEER 1). Insurance coverage for T2D indication may differ significantly from Wegovy.
GLP-1 agonists cause ~25–40% lean mass loss alongside fat. Resistance training 2–3×/week and high protein intake are the primary countermeasures. Clinical guidelines increasingly call this standard of care with any GLP-1 prescription.
Standard T2D combination. Complementary mechanisms (hepatic glucose output vs. incretin pathway). No overlapping toxicity. Most T2D patients continue both indefinitely.
Independent CV and renal benefits additive to semaglutide. SGLT2i add renal protection and modest weight loss. Common combination post-SELECT for cardiometabolic patients.
Proactive management of constipation: the most prevalent GI side effect. Community consensus: start fiber at treatment initiation before constipation develops, not reactively.
Overlapping mechanism doubles GI side effects without proportional benefit. Switch sequentially: do not use concurrently.
Do not combineGLP-1 receptor overlap: combining adds GI toxicity without additive benefit. Tirzepatide is a valid switch option if response to semaglutide is inadequate, but the two drugs must not overlap.
Do not combineSemaglutide enhances endogenous insulin secretion. Adding to existing insulin without reducing the insulin dose risks hypoglycemia. Standard: reduce insulin 20–30% at semaglutide initiation.
Delayed gastric emptying alters absorption timing and may destabilize INR. Monitor INR more frequently during semaglutide initiation and each dose increase.
Pricing updated 2026-04-09
Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation affects the majority of long-term users. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. FDA postmarketing warnings from September 2023 flagged three additional signals. Ileus (intestinal obstruction) requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm; 26% of SELECT participants had increases of 20 bpm or more. The 7.2 mg Wegovy HD dose introduced a new signal: dysesthesia (tingling, numbness) in 18.9% of patients vs. 0% on placebo in STEP UP. That adverse event profile is still being characterized. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. Contraindications: personal or family history of MTC or MEN2, history of pancreatitis, pregnancy or breastfeeding, hypersensitivity to semaglutide, severe gastrointestinal disease including gastroparesis. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia.
Verify Semaglutide dosing and safety with a second opinion
Brand-name Wegovy, Wegovy HD, and Ozempic are pharmaceutical-grade with consistent quality. Risk is entirely with compounded semaglutide: the FDA reported 455+ adverse events linked to compounded GLP-1 products by early 2025 (dosing errors, sterility failures). Semaglutide was removed from the FDA shortage list in February 2025, making 503A compounding legally prohibited from April 22, 2025. Despite this, many compounders continue operating via court challenges and clinical necessity exemptions as of April 2026. Counterfeit pens have been seized internationally.
| Test | When | Target |
|---|---|---|
| HbA1c (Glycated Hemoglobin) | Baseline; every 3 months until stable; then every 6 months | <5.7% (normoglycemic); <7.0% (T2D, per provider target) |
| Fasting Glucose + Insulin | Baseline and every 3–6 months | Fasting glucose 70–100 mg/dL; fasting insulin <25 mIU/L |
| Comprehensive Metabolic Panel (CMP) | Baseline, 3 months, then annually | eGFR >60 mL/min/1.73m²; ALT/AST within normal limits |
| Lipid Panel | Baseline and every 6 months | LDL <100 mg/dL (or <70 if high CV risk); TG <150 mg/dL; HDL >40 mg/dL (men), >50 mg/dL (women) |
| Thyroid Panel (TSH, free T4) ± Calcitonin | Baseline, then annually; calcitonin if thyroid nodule detected | TSH 0.4–4.0 mIU/L; calcitonin <10 pg/mL |
| Amylase + Lipase | Baseline; repeat immediately if severe abdominal pain develops | Amylase <100 U/L; lipase <60 U/L (lab-specific) |
| Resting Heart Rate | Baseline and every clinical visit | 60–100 bpm; flag any sustained increase >15 bpm from baseline |
| Body Composition (DEXA or validated BIA) | Baseline and every 6 months (every 3 months for Wegovy HD 7.2 mg) | Goal: lean mass loss <25% of total weight lost; maintain or increase skeletal muscle mass |
| Ophthalmology Exam (fundus) | Baseline for patients with pre-existing diabetic retinopathy; annually thereafter | No new progression from baseline |
Tracks long-term glycemic response. Semaglutide reduces A1c by 1.5–1.8% in T2D. Non-diabetic users benefit from a baseline reference to detect pre-diabetes improvement.
Real-time metabolic snapshot between A1c intervals. Fasting insulin captures improving insulin sensitivity before A1c changes are detectable.
Monitors renal function (creatinine, BUN, eGFR): AKI risk from GI-driven dehydration. Liver enzymes: gallbladder complications can elevate ALT/AST.
Semaglutide improves triglycerides and modestly improves LDL. Quantifies cardiometabolic benefit, especially for SELECT-indication patients.
Black box warning: rodent thyroid C-cell tumor signal. Calcitonin is the MTC screening marker. Also relevant for patients on levothyroxine: absorption may change with delayed gastric emptying.
Pancreatitis is rare but serious. Do not routinely rescreen asymptomatic patients: only with clinical suspicion.
Semaglutide increases resting HR by mean 1–4 bpm. In SELECT, 26% of patients had increases ≥20 bpm. Clinically relevant in arrhythmia history or rate-controlling medications.
GLP-1 agonists cause ~25–40% of weight lost as lean mass without resistance training. DEXA quantifies this and guides protein and training targets. Clinical guidelines increasingly endorse routine body composition monitoring.
FDA postmarketing warning (Sept 2023): rapid A1c improvement in T2D can paradoxically worsen diabetic retinopathy acutely. Monitor all patients with pre-existing retinopathy at initiation.
Titration phase. Mild appetite reduction begins. GI side effects (nausea) most common early. Body adjusts to GLP-1 activation.
Appetite suppression becomes noticeable. Early weight loss of 2-4%. Nausea typically subsides as dose stabilizes.
Significant hunger reduction and steady weight loss. Blood sugar and insulin sensitivity improve. Most patients lose 5-10% body weight.
Full therapeutic dose. Clinical trials show 15-17% average weight loss by week 68. Cardiovascular markers improve. Weight loss rate slows as new equilibrium is reached.
Long-term maintenance. Weight stability at reduced level while on therapy. Continued cardiovascular and metabolic benefits. Weight regain common if discontinued.
Weeks 1 through 4 (0.25 mg). This is a tolerability dose, not a therapeutic one. No real weight loss is expected. The point is to let GI receptors adjust before higher doses. Most people lose 2 to 5 lbs, mainly water and reduced intake. Some notice nothing. A minority gets hit with nausea from week one. The change that matters early is psychological: food thoughts become less intrusive. Common side effects are mild nausea (40 to 50% of patients), injection site redness, and fatigue. Weeks 5 through 8 (0.5 mg). The first pharmacologically active dose. Appetite suppression becomes measurable. Blood sugar improves in diabetic patients before the scale moves much. Community reports describe "food noise" noticeably quieting. Eating half-portions without effort is common. Weight loss picks up to 1 to 2 lbs per week. Nausea peaks in the first 2 to 3 days at each dose increase, then fades. Constipation typically starts here. Weeks 9 through 16 (1.0 to 1.7 mg). The community sweet spot. Strong appetite suppression, consistent scale movement, and visible physical changes around week 12. Energy improves. An unexpected finding shows up often in user reports: reduced alcohol tolerance and cravings, consistent with JAMA Psychiatry 2025 AUD RCT data [4]. Some users stay at 1.0 or 1.7 mg rather than escalating; appetite control is sufficient and side effects stay mild. Constipation is very common; sulfur burps and occasional heartburn are reported. Weeks 17 through 68 (2.4 mg maintenance). Weight loss continues but the rate slows. STEP 1 mean of 14.9% at week 68. Cardiovascular markers (CRP, blood pressure, waist circumference, triglycerides) keep improving. On the ground, weight loss becomes gradual at 0.5 to 1 lb per week. Plateaus lasting 2 to 4 weeks are normal and frustrating. "Ozempic face" becomes visible after 30+ lbs of total loss. Appetite suppression can work too well; some struggle to eat enough protein. Hair thinning from telogen effluvium peaks between months 3 and 6. Anxiety about stopping is a recurring theme even among highly satisfied users. Post-discontinuation. STEP 1 extension data showed two-thirds of weight returns within 1 year. Appetite comes back within 2 to 4 weeks. All cardiometabolic improvements reverse toward baseline within 12 months of stopping. Community experience confirms it: appetite floods back within weeks. About half maintain some loss at 1 year if strong exercise and dietary habits were built while on the drug. Stopping without a plan means regaining most or all of the weight. The psychological toll of regain is real and demoralizing for most who stop.
Sub-therapeutic dose: no meaningful weight loss expected. This dose primes GI receptors and reduces side effects at higher doses later.
Most lose 2–5 lbs (largely water and reduced intake). Some notice nothing. A minority gets significant nausea from week one. The notable early change is psychological: food thoughts become less intrusive.
First pharmacologically active dose. Appetite suppression measurable. Early glycemic improvement in T2D patients. Weight loss 2–4% from baseline.
"Food noise" noticeably quiets. Eating half-portions without effort is common. Weight loss picks up to 1–2 lbs/week. Nausea peaks in the first 2–3 days at each new dose increase, then fades. Constipation typically begins here.
Steady weight loss of 1–2% body weight/month. Lipid panels and blood pressure improving. Insulin sensitivity measurably better.
The community "sweet spot." Strong appetite suppression and consistent scale movement. Physical changes visible around week 12. Energy improves. Unexpected and widely reported: reduced alcohol tolerance and cravings. Some users stay at 1.0 or 1.7 mg rather than escalating: sufficient appetite control with fewer side effects.
Weight loss continues but decelerates. STEP 1 mean of 14.9% at 68 weeks. Cardiovascular markers (CRP, BP, waist circumference, triglycerides) continue improving.
Weight loss becomes gradual (0.5–1 lb/week). Plateaus of 2–4 weeks are normal and frustrating. "Ozempic face" becomes noticeable after 30+ lbs lost. Appetite suppression can work too well: some struggle to eat enough protein. Anxiety about stopping is a recurring theme even among highly satisfied users.
STEP 1 extension: two-thirds of weight regained within 1 year. Appetite returns within 2–4 weeks. All cardiometabolic improvements reverse toward baseline within 12 months of stopping.
Appetite floods back within weeks. Weight regain is demoralizing for most who stop. About half maintain some loss at 1 year if strong exercise and dietary habits were established while on the drug. Community consensus: stopping without a plan means regaining most or all of the weight.
Source: FDA Prescribing Information (Ozempic/Wegovy), Section 12.3
Loading the interactive decay curve.
Semaglutide has four active FDA approvals: Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), a cardiovascular risk reduction indication (March 2024 via SELECT data), and Wegovy HD 7.2 mg (March 2026). The oral Wegovy tablet received approval December 22, 2025 for chronic weight management. Rybelsus (oral, lower doses) holds a separate type 2 diabetes indication with CV risk extension added late 2024. Compounded semaglutide entered a complex legal environment. The FDA removed semaglutide from its drug shortage list on February 21, 2025. Enforcement deadlines followed: 503A compounding pharmacies faced an April 22, 2025 cutoff, 503B outsourcing facilities faced May 22, 2025. Despite those dates, many compounders continue operating through court challenges and clinical necessity exemptions. The FDA issued 55+ warning letters to telehealth companies in September 2025 for misleading advertising. Novo Nordisk sued Hims and Hers for patent infringement in February 2026. Legal status remains in flux. Semaglutide is on the WADA prohibited list under S2 (Peptide Hormones, Growth Factors). Athletes subject to anti-doping testing cannot use it. No FDA-approved biosimilar or generic exists. Key Novo Nordisk patents extend to 2033; earliest analyst estimates for biosimilar entry fall between 2028 and 2030. This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
